Navigation Links
AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
Date:8/11/2009

adult growth hormone deficiency. - Announcement that data from the Company's safety study of the Phase 3 program in BPH with cetrorelix are expected to be disclosed ahead of schedule, from the fourth quarter 2009 to the third quarter of 2009. - Completion of a registered direct offering of US$10 million of units comprised of common shares and common share purchase warrants to certain institutional investors. Subsequent to Quarter-End July - Publication in Proceedings of the National Academy of Sciences of new data supporting the use of the Company's ghrelin receptor antagonist compound, AEZS-123, for the treatment of alcohol dependence. August - Keryx, the Company's partner and licensee for perifosine in the North American market, reached an agreement with the FDA regarding a Special Protocol Assessment on the design of a Phase 3 trial with perifosine in multiple myeloma.

Juergen Engel, Ph.D., AEterna Zentaris President and Chief Executive Officer, commented, "The quarter was marked by continued progress of our current Phase 3 program in BPH with cetrorelix. As part of this same program and with a sponsorship from sanofi-aventis, our partner for cetrorelix in the US market, we initiated the extension of our North American efficacy study. We also moved up disclosure of the safety trial results of this program ahead of schedule, from Q4 to Q3 2009. Furthermore, we presented data on some of our anticancer compounds at both the AACR and ASCO annual meetings, which underlined the breadth and potential of our product pipeline. Also, we were very pleased with Keryx's announcement that they expect to begin a Phase 3 trial with perifosine in multiple myeloma, following their recent SPA agreement with the FDA. We now look forward to disclosing first results of our Phase 3 program in BPH during the third quarter, as we continue to deploy a
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015   GenoSpace , a leading provider ... analysis of genomic and other biomedical data, today ... the company as Vice President of Sales and ... "GenoSpace partners with its customers ... and explore complex sets of genomic, phenotypic and ...
(Date:7/30/2015)... , July 30, 2015   Aratana Therapeutics, ... therapeutics company focused on the licensing, development and ... today announced that its strategic partner VetStem Biopharma, ... confirmation study of AT-016, an adipose-derived allogeneic stem ... treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)...  Discovery Laboratories, Inc. (Nasdaq: DSCO ) ... $1.0M tranche under a previously awarded Phase II ... up to $3.0 million to support continued development ... potential medical countermeasure to mitigate acute and chronic/late-phase ... initial $1.0 million under this grant in October ...
(Date:7/29/2015)... , July 30, 2015 According ... Market - Growth, Trends & Forecasts (2015-2020), , published by ... US$ 30.25 billion by the end of 2020, with ... accounting for more than 40% of the global market size. ... at a CAGR of 13.7% during the period of (2015-2020). ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3
... Loestrin 24 Fe and Taclonex, ST. DAVID,S, Bermuda, ... today announced its results for the quarter and year,ended ... 31, 2007,totaled $227.7 million, an increase of 10.3%, over ... 31, 2007 totaled $899.6 million, an,increase of 19.2% over ...
... 29 Wyeth Pharmaceuticals,a division of Wyeth (NYSE: ... its,collaboration agreements with Solvay Pharmaceuticals for the development,and ... in earlier,stages of development for the potential treatment ... the collaboration with Solvay after assessing the,opportunity for ...
... SAN FRANCISCO, Calif., Feb. 28 ,Exelixis, Inc. (Nasdaq: ... director of investor relations, will present at the,Susquehanna SIGnificant ... a.m. PT on Tuesday, March 4, 2008., The ... the Event,Calendar page under Investors on the Exelixis website ...
Cached Biology Technology:Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 2Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 3Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 4Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 5Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 6Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 7Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 8Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 9Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 10Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 11Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 12Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 13Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 14Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 15Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 16Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 17Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds 2
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... today announced BD & Guidepoint Mentor, ... free access to Guidepoint,s expert network services. ... developing cutting-edge technologies to improve healthcare delivery and outcomes ... manager, each start-up entrepreneur will be able to directly ...
(Date:7/8/2015)... -- The consumer products industry for innovative tech ... such as wearables, smart wallets & other smart technology are ... continues to rapidly grow.  Biometrics & Wearable Device Companies in ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: AAPL ... GPRO ) and Baidu Inc. (NASDAQ: BIDU ) ...
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... Broadlawns Medical Center is reading palms in order to ... plan and commitment to be the Iowa leader in Electronic ... scanners to register and check-in patients. The new system, called ... Broadlawns Medical Center as part of a week-long launch.   ...
... children were born in public clinics in Denmark, projecting a net ... 50 years respectively. The authors of the study calculated that reductions ... to cost savings of 67 - 111 million for the Danish ... 50 years of age, the government would have lost 74 - ...
... Results from a study of over 50 000 pregnancies ... pregnancy was confirmed gave birth to babies with a ... never smoked, Professor Nick Macklon, from the Department of ... annual conference of the European Society of Human Reproduction ...
Cached Biology News:Broadlawns Installs First-in-Iowa Biometric Patient Identity Security System 2Broadlawns Installs First-in-Iowa Biometric Patient Identity Security System 3The long-term fiscal impact of funding cuts for IVF in Denmark 2Giving up smoking averts the adverse birth outcomes associated with tobacco 2
BD BioCoat Laminin 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
...
BD Primaria 100 mm Cell Culture Dish, surface-modified polystyrene for enhanced cell culture. (200/ca) Packaging: 20 / sleeve, 200 / case ...
The F40 piston assembly is supplied as two assemblies to service one F40 pump of a BioLogic DuoFlow workstation....
Biology Products: